Rare Neurological Disease Treatment Market to Gain US$ 12,000 Mn by 2026 : Pfizer Inc., Allergan Plc, Novartis AG, Bayer Aktiengesellschaft
In North America, rare neurological conditions are considered to a major healthcare concern, although fewer individuals are currently affected by the disease. Complexity of these diseases, along with their inadequacy in treatment options have led to disproportionate share of spending in healthcare.
View full press release